Press Releases

12.14.2016

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer

12.14.2016

Pfizer Announces FDA Approval of EUCRISA™ (crisaborole)

12.13.2016

Pediatric Open Innovation Challenge Grantees Awarded $50,000 by the Institute for Pediatric Innovation and Pfizer

12.13.2016

Ab Initio Announces Strategic Collaboration with Pfizer to Discover GPCR Activating Antibodies

12.13.2016

Pfizer Declares First-Quarter 2017 Dividend

12.12.2016

Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company Focused on Oncolytic Cancer Vaccine Discovery and Development

12.09.2016

Akili and Pfizer Present Positive Data from Digital Biomarker Study to Detect Subtle Cognitive Changes in Healthy Subjects at Risk of Developing Alzheimer’s Disease

12.06.2016

Pfizer Announces Expansion of ASPIRE Awards Program for 2017 to Include $5.5M in Funding for Breast and Hematologic Cancers

12.05.2016

Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

12.03.2016

Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting

12.03.2016

New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

12.01.2016

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference